A Phase 1 Study of GRN163L (Imetelstat) in Combination with Fludarabine and Cytarabine for Patients with Acute Myeloid Leukemia That Is in Second or Greater Relapse or That Is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or Is Refractory to Relapse Therapy